Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372489 | 1.00 | METAP2 (0.53) | METAP2RENACELMNAMEN1 | |
| SCHEMBL10956071 | 0.83 | METAP2 (0.49) | METAP2RENACELMNAMEN1 | |
| SCHEMBL10960502 | 0.81 | ACE (0.69) | RENACELMNAMEN1KMT2A | |
| SCHEMBL9593486 | 0.78 | ACE (0.60) | METAP2ACELMNAMEN1KMT2A | |
| SCHEMBL9593615 | 0.78 | ACE (0.71) | METAP2ACELMNAMEN1KMT2A | |
| SCHEMBL9594180 | 0.78 | ACE (0.51) | METAP2ACELMNAMEN1KMT2A | |
| SCHEMBL4458267 | 0.78 | ACE (0.49) | ACELMNAMEN1KMT2AUSP2 | |
| SCHEMBL1992431 | 0.78 | ACE (0.49) | ACELMNAMEN1KMT2AUSP2 | |
| SCHEMBL4458272 | 0.78 | ACE (0.49) | ACELMNAMEN1KMT2AUSP2 | |
| SCHEMBL13482629 | 0.78 | ACE (0.49) | ACELMNAMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284957-B1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2008-05-07 | — | — | EP | claimed |
| US-7071349-B2 | Purification method of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine | KANAKA CORPORATION (JP) | 2006-07-04 | — | — | US | claimed |
| EP-1284957-A4 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2004-12-29 | — | — | EP | claimed |
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1284957-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2003-02-26 | — | — | EP | claimed |
| WO-2002074728-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2002-09-26 | — | — | WO | claimed |
| CN-114002337-B | Method for detecting impurity G in enalapril maleate and application thereof | 株洲千金药业股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-114002337-A | Method for detecting impurity G in enalapril maleate and application thereof | 株洲千金药业股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-7375245-B2 | N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof | EVERLIGHT USA, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1284957-B1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-7071349-B2 | Purification method of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine | KANAKA CORPORATION (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20060009652-A1 | N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof | EVERLIGHT USA, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1284957-A4 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1284957-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002074728-A1 | PURIFICATION METHOD OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANINE | KANEKA CORPORATION (JP) | 2002-09-26 | — | — | WO | disclosed |
| US-5043346-A | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162991-A1 | Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine | ANPEP, NPEPPS, ADH1A | METAP2 46/4885REN 266/4885ACE 308/4885 |
| US-20060009652-A1 | N-(4-oxo-butanoic acid) -L-amino acid-ester derivatives and methods of preparation thereof | BCAT2, BCAT1, IL4I1 | METAP2 1088/4885REN 539/4885ACE 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.